Európska únia - islandčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - Æxlishemjandi lyf - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Európska únia - islandčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi, sérhæfður ónæmisbælandi - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Európska únia - islandčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Ónæmisörvandi, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Európska únia - islandčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - dímetýl fúmarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Island - islandčina - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - escitalopramum oxalat - filmuhúðuð tafla - 5 mg

Island - islandčina - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - darunavir propylene glycolate - filmuhúðuð tafla - 600 mg

Island - islandčina - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen pharma trading europe eood - vinorelbinum tvítartrat - mjúkt hylki - 30 mg

Island - islandčina - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - darunavir propylene glycolate - filmuhúðuð tafla - 800 mg

Island - islandčina - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - escitalopramum oxalat - filmuhúðuð tafla - 10 mg

Island - islandčina - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - escitalopramum oxalat - filmuhúðuð tafla - 15 mg